INSULIN-LIKE GROWTH-FACTORS IN BREAST AND PROSTATIC-CANCER

被引：7

作者：

HELLE, SI

LONNING, PE

机构：

[1] Dept. Therapeut. Oncol./Radiophysics, University of Bergen, Haukeland Hospital

来源：

关键词：

D O I：

10.1677/erc.0.0020153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IGF-I and IGF-II are both potent mitogens to breast and prostatic carcinoma cells. Evidence suggests that the disposition of IGF-I is different in patients suffering from advanced breast and prostatic carcinoma when compared with healthy controls. Steroid hormones and endocrine manipulation used in the treatment of breast and prostatic carcinomas may influence the plasma concentration of IGF-I and its binding proteins. However, due to the complex regulation of IGF bioavailability, it is difficult to evaluate the impact of alterations in IGFBPs. Further studies are warranted to evaluate the influence of hormone treatment on IGF-I, IGF-II and their binding protein in plasma and, in particular, in tumour tissue from patients suffering from breast and prostatic carcinomas. While most studies so far have evaluated the influence of short-term hormone therapy on the disposition of IGF-I, it would be of particular interest to look at the effect of long-term treatment, and to evaluate possible alterations in the IGF system in relation to the emergence of resistance to endocrine therapy.

引用

页码：153 / 169

页数：17

共 140 条

[1]

Adamo M., Shao Z.-M., Lanau F., Chen J.C., Clemmons D.R., Roberts C.T., LeRoith D., Fontana J.A., Insulin-like growth factor-I (IGF-I) and retinoic acid modulation of IGF-binding proteins (IGFBPs): IGFBP-2, -3, and -4 gene expression and protein secretion in a breast cancer cell line, Endocrinology, 131, pp. 1858-1866, (1992)

[2]

Arany E., Zabel P., Freeman D., Hill D.J., Elimination of radiolabelled human insulin-like growth factor binding protein-3 from the circulation, and its distribution amongst organs and tissues in adult male rats, Regulatory Peptides, 48, pp. 133-143, (1993)

[3]

Arteaga C.J., Kitten L.J., Coronado E.B., Jacobs S., Kull F.C., Allred D.C., Osborne C.K., Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice, Journal of Clinical Investigation, 84, pp. 1418-1423, (1989)

[4]

Ballard F.J., Ross M., Upton F.M., Francis G.L., Specific binding of insulin-like growth factors 1 and 2 to the type 1 and type 2 receptors respectively, Biochemical Journal, 249, pp. 721-726, (1988)

[5]

Bar R.S., Boes M., Clemmons D.R., Busby W.H., Sandra A., Dake B.L., Booth B.A., Insulin differentially alters transcapillary movement of intravascular IGFBP-1, IGFBP-2 and endothelial cell IGF-binding proteins in the rat heart, Endocrinology, 127, pp. 497-499, (1990)

[6]

Barni T., Vannelli B.G., Sadri R., Pupilli C., Ghiandi P., Rizzo M., Selli C., Serio M., Fiorelli G., Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: Gene expression and its cellular localization, Journal of Clinical Endocrinology and Metabolism, 78, pp. 778-783, (1994)

[7]

Baserga R., Sell C., Porcu P., Rubini M., The role of the IGF-I receptor in the growth and transformation of mammalian cells, Cell Proliferation, 27, pp. 63-71, (1994)

[8]

Baxter R.C., Characterization of the acid-labile subunit of the growth hormone dependent insulin-like growth factor binding protein complex, Journal of Clinical Endocrinology and Metabolism, 67, pp. 265-272, (1988)

[9]

Bennett A.E., Wahner H.W., Riggs B.L., Hintz R.L., Insulin-like growth factors I and II: Aging and bone density in women, Journal of Clinical Endocrinology and Metabolism, 59, pp. 701-704, (1984)

[10]

Berns E.M.J.J., Klijn J.G.M., Van Staveren I.L., Portengen H., Foekens J.A., Sporadic amplification of the insulin-like growth factor I receptor gene in human breast tumors, Cancer Research, 52, pp. 1036-1039, (1992)

← 1 2 3 4 5 6 7 8 9 10 →